Parkman Healthcare Partners LLC acquired a new position in Vir Biotechnology, Inc. (NASDAQ:VIR – Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 475,279 shares of the company’s stock, valued at approximately $4,843,000. Parkman Healthcare Partners LLC owned approximately 0.28% of Vir Biotechnology as of its most recent SEC filing.
A number of other large investors have also modified their holdings of the stock. AQR Capital Management LLC grew its holdings in Vir Biotechnology by 2,088.4% during the 1st quarter. AQR Capital Management LLC now owns 268,297 shares of the company’s stock valued at $1,739,000 after purchasing an additional 256,037 shares in the last quarter. Jacobs Levy Equity Management Inc. acquired a new position in shares of Vir Biotechnology in the first quarter worth about $359,000. Goldman Sachs Group Inc. boosted its holdings in Vir Biotechnology by 43.6% in the first quarter. Goldman Sachs Group Inc. now owns 742,674 shares of the company’s stock valued at $4,813,000 after purchasing an additional 225,544 shares during the last quarter. Woodline Partners LP boosted its holdings in Vir Biotechnology by 245.6% in the first quarter. Woodline Partners LP now owns 466,737 shares of the company’s stock valued at $3,024,000 after purchasing an additional 331,701 shares during the last quarter. Finally, Focus Partners Wealth grew its stake in Vir Biotechnology by 15.3% during the 1st quarter. Focus Partners Wealth now owns 19,317 shares of the company’s stock valued at $125,000 after purchasing an additional 2,566 shares in the last quarter. Institutional investors and hedge funds own 65.32% of the company’s stock.
Analyst Upgrades and Downgrades
Several equities analysts have recently commented on the company. Wall Street Zen upgraded Vir Biotechnology from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Morgan Stanley set a $25.00 price objective on shares of Vir Biotechnology in a research note on Thursday, August 6th. Leerink Partners raised their price objective on shares of Vir Biotechnology from $20.00 to $21.00 and gave the stock an “outperform” rating in a report on Wednesday, June 3rd. HC Wainwright reissued a “buy” rating on shares of Vir Biotechnology in a research report on Monday, August 10th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Vir Biotechnology in a research note on Wednesday, July 8th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Vir Biotechnology presently has an average rating of “Moderate Buy” and a consensus price target of $20.62.
Vir Biotechnology Trading Up 1.3%
Shares of NASDAQ VIR opened at $9.91 on Tuesday. The stock has a 50 day simple moving average of $9.44 and a 200-day simple moving average of $9.21. The company has a market cap of $1.68 billion, a PE ratio of -5.33 and a beta of 1.66. Vir Biotechnology, Inc. has a 12-month low of $4.35 and a 12-month high of $11.66.
Vir Biotechnology (NASDAQ:VIR – Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported $0.47 EPS for the quarter, beating the consensus estimate of $0.33 by $0.14. The firm had revenue of $238.95 million for the quarter, compared to analysts’ expectations of $135.88 million. Vir Biotechnology had a negative return on equity of 29.99% and a negative net margin of 638.88%.The firm’s revenue was up 19582.5% compared to the same quarter last year. During the same period last year, the firm earned ($0.80) EPS. Sell-side analysts forecast that Vir Biotechnology, Inc. will post -1.84 earnings per share for the current fiscal year.
Insider Activity
In other news, Director Janet Napolitano sold 3,200 shares of the stock in a transaction on Monday, June 1st. The stock was sold at an average price of $9.45, for a total value of $30,240.00. Following the completion of the transaction, the director owned 21,216 shares of the company’s stock, valued at approximately $200,491.20. This represents a 13.11% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 2.90% of the company’s stock.
About Vir Biotechnology
Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.
The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.
Further Reading
- Five stocks we like better than Vir Biotechnology
- Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters
- Treasury Yields Are Surging Again: 3 Stocks That Could Feel the Pain
- Snowflake Could Be Headed for New Highs Despite Insider Selling
- MongoDB Is Surging—And the Next Catalyst Is Almost Here
Receive News & Ratings for Vir Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vir Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
